Two‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5
Authors' conclusion
In adults with overweight/obesity, semaglutide 2.4 mg improved short- and longer-term control of eating associated with substantial weight loss.
Study context
- Population
- Adults with overweight/obesity in STEP 5; subgroup completing the 19-item Control of Eating QuestionnaireCOEQ completers
- Participants
- 88 vs 86
- Comparison
- Once-weekly semaglutide 2.4 mg vs placebo, plus lifestyle modification, for 104 weeks
- Semaglutiden = 88
- Placebon = 86reference
- Primary endpoint
- Control of eating (19-item Control of Eating Questionnaire)
- Follow-up
- 2 years
Methodological detailsrandomized 1:1, P values not controlled for multiplicity
- Randomized 1:1
- P values not controlled for multiplicity
Primary result
As reported in the abstract
Control of Eating Questionnaire domain scores · weeks 20, 52 and 104
- Semaglutide vs Placebo: P < 0.01
- Semaglutide vs Placebo: P < 0.05
- Semaglutide vs Placebo: P < 0.001
- P values not controlled for multiplicity
Further findings
Mean, %
| Outcome | Semaglutide | Placebo |
|---|---|---|
| Mean body weight change | −14.8 | −2.4 |
- Desire for salty/spicy food, cravings for dairy and starchy foods, difficulty resisting cravings, control of eating · 104 weeks · scores significantly reduced with semaglutide
- all p < 0.05
Craving domain scores vs weight · baseline to week 104
- Improvements in craving domain scores positively correlated with body weight reductions with semaglutide
Original publication
Two‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity (Silver Spring). Published 18 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →